Recent federal court rulings to restrict use of FDA-approved drug mifepristone are inconsistent with evidence on safety and efficacy
Recent decisions regarding approval of the FDA-approved drug mifepristone contradicts over 100 peer-reviewed studies. The drug has been used to safely and effectively induce abortion and treat miscarriages among over five million Americans. There is no scientific basis for denying access.
As an institution whose work centers around scholarship and science for social change, we do not support decisions to restrict access to mifepristone or abortion. Our work has global reach, and we fear for the health and well-being of pregnant people in countries that have outlawed and restricted access to abortion, including the United States. We remain committed to supporting reproductive health and rights worldwide for all.
About Gates Institute
Located in the Department of Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health, the Gates Institute is dedicated to the advancement of scholarship and science for social change. The Institute conducts and facilitates cutting-edge research in family planning, adolescent and youth reproductive health and population dynamics, and translates science into evidence-informed policies, programs and practice.
For more information, please visit www.gatesinstitute.org.
Read Gates Institute’s statement on the 2022 US Supreme Court decision to overrule 50 years of precedent for abortion rights.
